272 related articles for article (PubMed ID: 17396041)
1. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
2. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
3. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
4. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Min WS; Shin WS
Korean J Intern Med; 2006 Sep; 21(3):165-72. PubMed ID: 17017665
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial.
Saito AM; Yoshida I; Tanaka S; Sawamura M; Hidaka M; Yoshida S; Uike N; Kaneko Y; Miyazaki Y; Nagai H
Kurume Med J; 2021 Dec; 66(4):239-246. PubMed ID: 34544939
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE
Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
Harousseau JL; Dekker AW; Stamatoullas-Bastard A; Fassas A; Linkesch W; Gouveia J; De Bock R; Rovira M; Seifert WF; Joosen H; Peeters M; De Beule K
Antimicrob Agents Chemother; 2000 Jul; 44(7):1887-93. PubMed ID: 10858349
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
13. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
15. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever.
Yoshida I; Saito AM; Tanaka S; Choi I; Hidaka M; Miyata Y; Inoue Y; Yamasaki S; Kagoo T; Iida H; Niimi H; Komeno T; Yoshida C; Tajima F; Yamamoto H; Takase K; Ueno H; Shimomura T; Sakai T; Nakashima Y; Yoshida C; Kubonishi S; Sunami K; Yoshida S; Sakurai A; Kaneko Y; Miyazaki Y; Nagai H
Mycoses; 2020 Aug; 63(8):794-801. PubMed ID: 32391919
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS; Cheong JW; Kim YK; Park J; Mun YC; Kang HJ; Yi HG; Lee JH; Kim YS; Ryoo HM; Kim SH; Kim HY; Kim JY; Lee DG; Kim HG; Kim H; Joo YD; Min YH
Ann Hematol; 2014 Jan; 93(1):33-42. PubMed ID: 23807252
[TBL] [Abstract][Full Text] [Related]
17. Summaries for patients. Itraconazole and amphotericin B to treat fungal infections in patients with cancer who are receiving chemotherapy.
Ann Intern Med; 2001 Sep; 135(6):S-39. PubMed ID: 11575279
[No Abstract] [Full Text] [Related]
18. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
Martino R; Viscoli C
Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
[TBL] [Abstract][Full Text] [Related]
19. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
20. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients.
Boogaerts M; Maertens J; van Hoof A; de Bock R; Fillet G; Peetermans M; Selleslag D; Vandercam B; Vandewoude K; Zachée P; De Beule K
J Antimicrob Chemother; 2001 Jul; 48(1):97-103. PubMed ID: 11418517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
